A randomised controlled study comparing adebelimab plus Disitamab Vedotin and carboplatin versus nab-paclitaxel plus carboplatin in the neoadjuvant treatment of HER2-low breast cancer

Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2025
This article has no abstract
Epistemonikos ID: 689b0fc6eef14d66ef6fd3889564ba5a017e3412
First added on: Apr 26, 2025